Multicenter, randomized, parallel group open study to compare, in patients with postmenopausal osteoporosis, the effects of clodronate (Difosfonal) administered either intramuscularly at a dose of 100 mg 1 weekly, intramuscularly at a dose of 200 mg once every 2 weeks or orally at a dose of 800 mg daily (400 mg x 2), on BMD and markers of bone metabolism.

Trial Profile

Multicenter, randomized, parallel group open study to compare, in patients with postmenopausal osteoporosis, the effects of clodronate (Difosfonal) administered either intramuscularly at a dose of 100 mg 1 weekly, intramuscularly at a dose of 200 mg once every 2 weeks or orally at a dose of 800 mg daily (400 mg x 2), on BMD and markers of bone metabolism.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2012

At a glance

  • Drugs Clodronic acid (Primary) ; Clodronic acid (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jun 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top